One Biosciences raises €15 million Series A to drive clinical single‑cell oncology profiling

One Biosciences, a Paris‑based precision oncology techbio spin‑out from Institut Curie founded in 2020, has secured €15 million in a Series A funding round. Co‑led by Redmile Group and Blast, the round also saw participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. These funds will advance the clinical and strategic development of its flagship OneMap™ platform—an AI‑powered, single‑cell transcriptomic tool designed to decode tumour heterogeneity in routine biopsy samples.

OneMap™ aims to deliver high-resolution tumour profiles within two weeks to guide treatment decisions, improve patient selection, support therapy development, and optimise clinical trials . One Biosciences has already raised over €20 million including seed funding from Home Biosciences and boasts strategic partnerships with Institut Curie, Gustave Roussy and AP‑HP hospitals.

CEO Hedi Ben Brahim says this financing will “translate our breakthrough single‑cell technology into real‑time insights” for doctors and pharma partners. Institut Curie’s technology transfer office highlights One Biosciences’ journey from incubator to frontrunner in single‑cell AI diagnostics.